Publication date: Aug 17, 2019
Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.
Queirolo, P., Boutros, A., Tanda, E., Spagnolo, F., and Quaglino, P. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. 23816. 2019 Semin Cancer Biol.
- Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.
- New paradigm for stage III melanoma: from surgery to adjuvant treatment.
- HO-1 downregulation favors BRAF melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition.
- Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.
- Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.
- Featured Review: Evidence for the benefits and harms of screening for malignant melanoma